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ABSTRACT
Background To evaluate the efficacy of Bacilli 
Calmette-Guerin (BCG) induction instillation therapy 
after second transurethral resection (TUR) in stage Ta 
T1 high-grade bladder cancer.
Methods We performed a retrospective analysis of 49 
consecutive new onset Ta T1 high-grade bladder cancer 
patients treated with second TUR at our affiliated insti-
tutions. Residual cancer rate, intravesical recurrence-
free survival (RFS), and risk factors related to RFS 
were evaluated by univariate and multivariate Cox 
proportional hazard model analyses.
Results Thirty-one patients received BCG therapy af-
ter the second TUR (BCG group), and 18 patients were 
treated with second TUR alone (no BCG group). There 
were statistically significant differences in the RFS rates 
between the two groups, (P = 0.037). BCG therapy was 
the only factor predictive of intravesical recurrence 
after second TUR in both univariate and multivariate 
analyses. After the second TUR, BCG therapy signifi-
cantly decreased intravesical recurrence in the patients 
with residual tumors (P = 0.014). However, there was 
no significant difference in intravesical recurrence in 
the patients with no residual tumors between the two 
groups (P = 0.359).
Conclusion BCG therapy after second TUR signifi-
cantly decreased intravesical recurrence of residual 
tumors found at the second TUR.
Key words bacilli calmette-guerin therapy; bladder 
cancer; second transurethral resection
High-grade non-muscle invasive bladder cancer 
(NMIBC) give some epidemiological data. The recur-
rence rate after transurethral resection of bladder tumor 
(TURBT) has been reported to be approximately 
60%–70%.1–3 The standard treatment for high-grade 
pT1 bladder cancer following TURBT was the intra-
vesical Bacilli Calmette-Guerin (BCG) therapy before 
a second transurethral resection (TUR) was selected. 
This has decreased the recurrence rate to approximately 
30%–50%.4, 5 For high risk groups in bladder cancer 
progression, the European Association of Urology 
guidelines indicate cystectomy or intravesical BCG 
therapy as the standard treatments.6 Cystectomy is a 
typical treatment that patients with high risk for blad-
der cancer can follow. Additionally, it is an option for 
patients with low efficacy of BCG. For this reason, 
after TURBT for patients with high-grade pT1 bladder 
cancer, BCG induction therapy is chosen as the next 
treatment.
In several series of second TUR for bladder cancer, 
recurrence-free survival (RFS) was very different 
between patients who received a second TUR and those 
who received a single TUR. In the prospective random-
ized study by Divrik et al (2010), 5y RFS of patients 
who had only T1 bladder cancer, who received a second 
TUR was 59% and those who received a single TUR 
was 32% (P < 0.001).7 According to the guidelines of 
the European Association of Urology, second TUR is 
recommended for those patients who have high-grade 
Ta T1 tumors in the bladder.6 Furthermore, in the 
National Comprehensive Cancer Network guidelines, 
if an accurate staging cannot be obtained in the first 
TUR or if there is no specimen including muscle layer 
in the TUR specimen, repeat resection is recommended 
for high grade pTa bladder cancers and any pT1 bladder 
cancers.8 According to these results, a single TUR alone 
may underestimate muscle invasive cancers, which may 
result in inadequate treatment. Considering the above, a 
second TUR is recommended for accurate diagnosis of 
disease and improvement of outcome in high-grade T1 
bladder cancer.
As described above, the efficacy of second TUR 
Original ArticleYonago Acta Medica 2019;62(2):191–197 doi: 10.33160/yam.2019.06.003
191
Corresponding author: Masashi Honda, MD, PhD
honda@tottori-u.ac.jp
Received 2019 January 31
Accepted 2019 May 8
Online published 2019 June 20
Abbreviations: BCG, Bacilli Calmette-Guerin; BMI, body mass 
index; CI, confidence intervals; CIS, concomitant carcinoma in 
situ; HRs, hazard ratios; NMIBC, non-muscle invasive bladder 
cancer; RFS, recurrence-free survival; TURBT, transurethral 
resection of bladder tumor
© 2019 Tottori University Medical Press
Y. Kimura et al.
and BCG induction instillation therapy after (first) TUR-
Bt in high-grade Ta T1 bladder cancers were shown. 
However, the adaptation and effects of BCG therapy af-
ter the second TUR in high-grade Ta T1 bladder cancer 
have not been fully considered. In particular, it is essen-
tial to determine if BCG induction instillation therapy 
is necessary for patients with no residual tumor at the 
second TUR. As far as we could search, there was only 
one study that has examined BCG therapy after second 
TUR. Thus, the aim of this study was to investigate the 
effects of BCG therapy after second TUR in high-grade 
Ta T1 bladder cancer. Furthermore, the effects of BCG 
therapy in patients with no residual tumors after the 
second TUR were evaluated.
MATERIALS AND METHODS
In this study, data were collected from five institutes, 
from June 2006 up to April 2015. Informed consent was 
obtained from all individual participants included in the 
study. In total, 60 patients were newly diagnosed with 
Ta T1 high-grade bladder cancer at the first TUR and 
who received a second TUR. We excluded one patient 
who received intravesical chemotherapy after the second 
TUR, five patients who underwent cystectomy before 
intravesical recurrence, and five patients with a past his-
tory or complication of upper tract urothelial carcinoma. 
Excluding these patients, we retrospectively analysed 
49 patients in a non-randomized study. All of the 49 
patients underwent a second TUR within approximately 
4–6 weeks following the first TUR. In the second TUR, 
deep resection was performed to obtain muscle in the 
pathological specimen with a tumor margin of approxi-
mately one cm.
Among the 49 patients, 31 received BCG induction 
instillation within 2–4 weeks after the second TUR 
(BCG group), and 18 patients received no therapy after 
the second TUR (no BCG group). The reasons for 
no BCG therapy after the second TUR were, clinical 
decisions made by the attending physician in 13 cases, 
old age in 3 cases, and patient rejection in 2 cases. 
BCG consisted of one instillation weekly for 8 weeks. 
Cystoscopy and urinary cytology were performed 
4–6 weeks after the BCG therapy, and a biopsy was 
performed if there was an abnormality. Patients were 
followed by urinary cytology and cystoscopy every 
three months in the first two years, every six months in 
the third to fourth year, and every 12 months in the fifth 
year and later. No patients received maintenance BCG 
therapy.
We checked the medical records with attention 
to patient characteristics, tumor status at first TUR, 
pathological findings of the second TUR, and adjuvant 
therapy after the second TUR. Tumor size was defined 
as the maximum tumor dimension estimated at the 
time of TURBT and/or by clinical imaging. The 
numbers of tumors were estimated in the same manner. 
Concomitant carcinoma in situ (CIS) was revealed in 
the surgical pathology of TURBT. The clinical T stage 
and grade of the bladder were determined according 
to the 2002 TNM classification of bladder tumors. 
The pathological examination for bladder tumor was 
performed by pathologists at each institution.
We performed the chi-square test to compare the 
following patient background factors between the 2 
groups. The primary end point of this study was the first 
intravesical recurrence. We estimated the RFS by using 
the Kaplan–Meier method and compared them between 
the 2 groups by performing the log-rank test. Univariate 
and multivariate analyses using a Cox proportional 
hazards regression model were used to analyze the 
potential risk factors for the intravesical recurrence after 
the second TUR.
Estimated hazard ratios (HRs) with their respec-
tive 95% confidence intervals (CI) were defined for 
each variable analyzed. We used IBM SPSS Statistics 
for Windows (version 23.0; IBM, Armonk, NY) for 
statistical analyses. A P-value < 0.05 was considered as 
indicating statistical significance.
RESULTS
The median follow-up period for the 49 patients was 
34.0 months (range, 8.7–117 months). This study in-
cluded 41 male and eight female patients. In Table 1, the 
patients’ characteristics are presented. Of the 49 patients 
after second TUR, residual tumors (pTa, pT1, and pTis) 
were detected in 21 patients (42.9%), and no residual 
tumor (pT0) was found in 28 patients (57.1%). The rates 
of residual tumor were 53.8% in pTa and 38.9% in pT1. 
In the patients with high-grade pTa at the initial TUR, 2 
patients were upstaged to pT1 at the second TUR.
Of the 49 patients, 13 (26.5%) developed intravesi-
cal recurrences. The median period until intravesical 
recurrence was 6.8 months (range, 3.6–35.6 months). 
The RFS rate was 79.5% at 1 year, 75.2% at 2 years, and 
70.8% at 3 years.
At the second TUR, six patients were pT1, among 
whom two patients were pTa, and four were pT1 at the 
initial TUR. Intravesical recurrence was observed in 
three of the six (Ta, one patient; T1, two patients at the 
initial TUR), and all three of these patients underwent 
subsequent total cystectomy. Interestingly, these three 
patients did not receive add-on BCG after the second 
TUR, but three patients without recurrence did.
In Table 2, the patients’ background factors and 
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the chi-square test results of the 2 groups are presented. 
Differences were found in concomitant CIS (P = 0.01) 
and tumor size (P = 0.04) between the two groups.
In Table 3, the results of univariate and multivariate 
analysis to predict the risk factors for intravesical recur-
rence are shown. BCG was the only factor predictive of 
intravesical recurrence after the second TUR in both the 
univariate and multivariate analyses. In this study, there 
were no preoperative factors predictive of intravesical 
recurrence.
The results of the intravesical RFS after the second 
TUR for the two groups (BCG vs. no BCG) determined 
by the Kaplan–Meier method and log-rank test are 
shown in Fig. 1. The 1-year RFS rates of the two groups 
were 84% (BCG group) and 61% (no BCG group). 
The RFS period was significantly longer for the BCG 
group than for the no BCG group (P = 0.037) (Fig. 1A). 
In 40 patients, excluding concomitant CIS, the RFS 
was significantly longer for the BCG group (n = 22) 
compared to the no BCG group (n = 18) (P = 0.035) (Fig. 
1B). For tumor maximum diameters at initial TUR of 
< 3 cm, there was a tendency of recurrence suppres-
sion effect in the BCG group versus the no BCG group 
(P = 0.082), but there was no significant difference in 
recurrence between the two groups for tumor maximum 
diameters at initial TUR of ≥ 3 cm (P = 0.356). We also 
analysed the intravesical RFS rates between the two 
groups (BCG vs. no BCG) for the presence or absence 
of residual tumor after the second TUR. There was a 
significant recurrence suppression effect in the BCG 
group (P = 0.014) (Fig. 1C) in the patients with residual 
tumor after the second TUR, but there was no signifi-
cant difference between the two groups in the patients 
with no residual tumor (P = 0.359) (Fig. 1D).
193 © 2019 Tottori University Medical Press
Table 1. Patients' characteristics of 49 patients with bladder cancer who underwent a second TUR
Variables No. (%) of patients
Age (y) 73.9 (47–91)
BMI (kg/m2) 22.6 (16.1–28.4)
Age-adjusted CCI 4 (0–8)
Sex Male 
Female
 41 (83.7) 
 8 (16.3)
Smoking With 
Without
 31 (63.3) 
 17 (34.7)
Hydronephrosis With 
Without
 3 (6.1) 
 46 (93.9)
Urine cytology > III 
≤ III
 27 (55.1) 
 21 (42.9)
Single immediate instillation of intravesical  
chemotherapy after initial TUR
Without 
Pirarubicin 
Epirubicin
 33 (67.3) 
 15 (30.6) 
 1 (2.0)
First pTstage pTa 
pT1
 13 (26.5) 
 36 (73.5)
Histology Urothelial cancer 
Adenocarcinoma 
Squamous cell carcinoma
 46 (93.9) 
 2 (4.1) 
 1 (2.0)
Tumor grade G1 
G2 (> G3) 
G3 (> G2)
0 (0)
 28 (57.1) 
 21 (42.9)
Concomitance of CIS With 
Without
 9 (18.4) 
 40 (81.6)
Tumor size < 3 cm 
≥ 3 cm
 35 (71.4) 
 13 (26.5)
Number of tumors 1 
≥ 2
 19 (38.8) 
 29 (59.2)
BMI, body mass index; CCI, charlson comorbidity index; CIS, concomitant carcinoma in situ; TUR, transurethral resection; y, years.
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Table 2. Patient background factors and the chi-square test results
Second TUR alone Second TUR + BCG P-value
n = 18 n = 31
Age (y) < 76 
≥ 76
 9 
 9
 15 
 16
.574
Sex Male 
Female
 15 
 3
 26 
 5
.628
Urine cytology < IV 
≥ IV
 7 
 10
 14 
 17
.517
Tumor size < 3 cm 
≥ 3 cm
 10 
 8
 25 
 5
.040
Number of tumors Single 
Multiple
 8 
 10
 11 
 19
.408
pTstage after initial TUR pTa 
pT1
 2 
 16
 9 
 22
.136
Concomitant CIS With 
Without
 0 
 18
 9 
 22
.010
Single immediate instillation of  
intravesicalchemotherapy
With 
Without
 5 
 13
 11 
 20
.410
Residual tumor after second TUR With 
Without
 5 
 13
 16 
 15
.920
BCG, bacilli calmette-guerin; CIS, concomitant carcinoma in situ; TUR, transurethral resection; y, years.
Table 3. Univariate and multivariate analyses of preoperative and postoperative parameters predicting  
intravesical recurrence
Multivariate
Parameter  Cutoff Univariate 
P value
Hazard ratio 95% CI P-value
Age (y) < 76 vs ≥ 76 0.692 0.772
BMI (kg/m2) < 25 vs ≥ 25 0.324 0.487
Age-adjusted CCI < 4 vs ≥ 4 0.395 0.137
Sex Male vs female 0.355 0.486
Smoking With vs without 0.618 0.713
Urine cytology < IV vs ≥ IV 0.054 0.125
Tumor size < 3 cm vs ≥ 3 cm 0.158 0.599
Number of tumors Single vs multiple 0.574 0.605
Histological history UC vs non UC 0.895 0.780
Initial TUR pTstage Ta vs T1 0.527 0.451
Concomitant CIS With vs without 0.751 0.915
Single immediate instillation of  
intravesical chemotherapy after  
initial TUR
With vs without 0.700 0.393
BCG after second TUR Without vs with 0.013 3.736 1.124–12.423 0.032
Residual tumor after second TUR With vs without 0.453 0.873
BCG, bacilli calmette-guerin; BMI, body mass index; CCI, charlson comorbidity index; CI, confidence interval; CIS, concomitant 
carcinoma in situ; TUR, transurethral resection; UC, urothelial carcinoma; y, years.
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DISCUSSION
Many studies have reported that a second TUR for 
high-grade bladder cancer can prevent intravesical 
recurrence and enable detection of staging errors and 
residual tumors, therefore second TUR is strongly 
recommended for high-grade T1 bladder cancer. The 
results of the procedure can be useful in the decision-
making process for subsequent management, including 
watchful follow-up, adjuvant intravesical therapy, or 
cystectomy.9 The rates of residual tumor and upstaging 
after the second TUR have varied between 28%–74% 
and 1.7%–64%, respectively.1, 10–14 In our study, with 
the exclusion of some cases, the rate of residual tumor at 
the second TUR was 42.9%. When the excluded cases 
were included (n = 60), the rates of residual tumor and 
upstaging to muscle invasive at the second TUR were 
50.0% and 1.7%, respectively, which are comparable 
with those of the previous studies cited above.
For high-grade Ta disease, the First International 
Consultation on Bladder Tumors recommends one 
immediate chemotherapy instillation after TURBT, 
followed two to four weeks later by repeat TURBT 
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Fig. 1. Kaplan–Meier curves of recurrence-free survival in patients who received BCG instillation therapy after the second TUR and 
those who received the second TUR alone (no BCG) (A) in all patients (n = 49); (B) in patients without concomitant CIS (n = 40); (C) in 
patients with residual tumors after the second TUR (n = 21); and (D) in patients with no residual tumor after the second TUR (n = 28). 
BCG, bacilli calmette-guerin; CIS, concomitant carcinoma in situ; TUR, transurethral resection.
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and bladder mapping biopsy.15 The standard American 
Urological Association approach to high-grade Ta, T1, 
and/or CIS primary bladder cancer after initial TURBT 
is second TUR before additional intravesical therapy.16 
In our study, at the first TUR, not only high-grade T1 
but also Ta occurred at half of the residual tumor rate 
after the second TUR. Two patients were upstaged to 
pT1 in the case of high-grade Ta at the initial TUR, and 
one of the two had undergone total cystectomy after 
intravesical recurrence. For the reasons above, although 
the sample size was small, we think that it is better to 
perform a second TUR not only for T1 but also Ta in 
high-grade.
The European Organization for Research and 
Treatment of Cancer has reported that are several 
characteristics of risk factors which have a role in the 
intravesical recurrence of NMIBC.17 Presence of con-
comitant CIS, prior recurrence rate, the size of the tumor 
and the multiplicity were risk factors for intravesical re-
currence in patients with Ta T1 bladder cancer who did 
not undergo TUR for the second time neither received 
maintenance therapy with instillation BCG. In another 
study, patients with high-grade T1 bladder cancer who 
had not undergone a second TUR, the location of the 
tumor was the risk factor for intravesical recurrence.18 
In our study, there were no significant differences in in-
travesical recurrence for the examined preoperative risk 
factors, including tumor size, tumor number, and tumor 
grade; only BCG instillation therapy was significantly 
associated with intravesical recurrence.
When pT1 disease is found at the second TUR, the 
question of which treatment should be added is contro-
versial, particularly regarding cystectomy. Herr et al 
(2007)3 reported that patients with T1 remaining at the 
second TUR were more likely to progress even if BCG 
therapy was administered. For such cases, immediate 
cystectomy was proposed along with careful follow-up 
observation and the state of the residual tumor to decide 
on the most appropriate management. With reference to 
these findings, because the patients with high-grade T1 
bladder cancer who undergo a second TUR are higher 
risk for progression, cystectomy at an early stage has 
more possibility to lead to cure. On the contrary, an-
other study demonstrated that there was no significant 
difference in the survival rate between the patients who 
received early cystectomy and those who continued 
follow-up without cystectomy until they needed it.19 In 
the present study, bladder function was preserved in 
all three T1 patients receiving BCG induction therapy 
after the TUR for the second time. At the mention of the 
complications associated with chemotherapy, cystec-
tomy or radiation therapy, the adequate BCG induction 
therapy is one reasonable treatment option for careful 
management.
In the retrospective study by Iida et al (2016)20 
where all the patients had new onset high-grade T1 
bladder cancer, BCG therapy was the strongest factor 
predictive of intravesical RFS after the second TUR in 
both univariate and multivariate analyses. In that study, 
the 1- and 3-year RFS rates were 83% and 77% for BCG 
after the second TUR, respectively, and 60% and 32% 
for second TUR alone, respectively. The researchers 
concluded that even if the pathology of the second TUR 
was pT0, BCG therapy following a second TUR de-
creased intravesical recurrence.20 On the other hand, in 
our study, although the RFS rates tended to be higher in 
the BCG group than those in the no BCG group, there 
was no significant difference in the RFS rates between 
the groups for the patients with no residual tumor at the 
second TUR. The reason for this discrepancy between 
our results and the results from the study by Iida et al20 
(2016) is that our institution performed a more complete 
resection. The number of recurrent cases at the second 
TUR with no BCG and no residual tumor was 11 (58%) 
of 19 in the study by Iida et al previously cited study, 
whereas it was 5 (38.5%) of 13 in our study.
Our study has some limitations. It is a non-
randomized, retrospective, multi-center study in a small 
number of patients. There was variation in the TUR 
procedures among the institutions, and the pathological 
results also may have varied. Additionally, the indica-
tions for introducing BCG were not consistent among 
the different institutions. We did not consider whether 
the recurrence site was located at the second TUR area 
at another area and finally, we did not perform mainte-
nance BCG after the second TUR.
BCG therapy after the second TUR in Ta T1 high-
grade bladder cancer significantly decreased intravesi-
cal recurrence. However, in patients with no residual 
tumor after the second TUR, there was no significant 
difference in RFS rates between patients who received 
second TUR with BCG therapy and those who received 
the second TUR alone.
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